Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.

ABSTRACT: Ipilimumab, the first immune-checkpoint inhibitor extending overall survival (OS) in metastatic melanoma patients, has a survival benefit only in a proportion of patients and the development of reliable predictive biomarkers is still an unmet need. To meet this request, we used a multivariate statistical approach to test whether myeloid-derived suppressor cells (MDSC) or other tumor-associated and immunological parameters may serve as predictive or prognostic biomarkers in melanoma patients receiving ipilimumab. By using a standardized approach to determine the circulating levels of four MDSC subsets, we observed a significant expansion of three MDSC subsets at baseline, as compared to controls and, upon treatment, that high levels of CD14⁺/IL4Rα⁺ MDSCs were an indepe

SUBMITTER: Damuzzo V 

PROVIDER: S-EPMC5215225 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature